Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aezea with Chemotherapy for Refractory AML in Older Adults
NCT00967512Phase 2Withdrawn
- Sponsor
- Eleos Health
- Start
- Jan 2012
- Primary completion
- Jan 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
A Phase 2 trial of cenersen sodium in acute myeloid leukemia (AML), sponsored by Eleos Health. Planned start Jan 2012; status: withdrawn.
02
Drugs
cenersen sodium
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00967512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967512.